Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab
| Autor: | Stephen Tattersall, Serigne Lo, Richard A. Scolyer, K. Nahar, Neomal S. Sandanayake, Alexander M. Menzies, Christopher J. Kiely, Georgina V. Long, Robert V. Rawson, Umaimainthan Palendira, Matteo S. Carlino, Tasnia Ahmed |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Adult Male CTLA-4 antigen Cancer Research medicine.medical_specialty medicine.medical_treatment Immunology Programmed Cell Death 1 Receptor Ipilimumab Gastroenterology 03 medical and health sciences 0302 clinical medicine Antineoplastic Agents Immunological Internal medicine medicine Immunology and Allergy Humans Colitis Adverse effect RC254-282 Aged Pharmacology Aged 80 and over Clinical/Translational Cancer Immunotherapy biology business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens Immunosuppression Immunotherapy Middle Aged medicine.disease Discontinuation 030104 developmental biology Oncology inflammation 030220 oncology & carcinogenesis Toxicity biology.protein Molecular Medicine Female immunotherapy Antibody business medicine.drug |
| Zdroj: | Journal for Immunotherapy of Cancer Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020) |
| ISSN: | 2051-1426 |
| Popis: | BackgroundColitis is one of the common immune-related adverse events that leads to morbidity and treatment discontinuation of immunotherapy. The clinical presentation, endoscopic and histopathological features and best management of this toxicity are not well defined.Patients and methodsPatients with metastatic melanoma who received immunotherapy (programmed cell death protein 1 (PD1) antibodies, alone or in combination with a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody (PD1 +CTLA-4)) and who developed clinically significant colitis (requiring systemic corticosteroids) were identified retrospectively from two academic centers. Clinical data were collected for all patients; endoscopic and histopathological data were examined in a subset.ResultsFrom May 2013 to May 2019, 118/1507 (7.8%) patients developed significant colitis; 80/553 (14.5%) after PD1+CTLA-4, 35/1000 (3.5%) PD1 alone, and three patients after Ipilimumab (IPI) alone. Combination therapy-induced colitis was more frequent (14.5% vs 3.5% in PD1 alone, p=ConclusionClinically significant colitis varies in presentation, response to immunosuppression, and endoscopic/histologic features depending on the immunotherapy type. Infliximab-refractory colitis occurs early, is often high grade, and has adverse endoscopic and histopathologic features |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|